MEMORANDUM & ORDER
St. John’s University (“Plaintiff’ or “St. John’s” or “the University”) brings this action alleging that Sanford Bolton (“Bolton”) and Spiridon Spireas (“Spireas”) deliberately concealed, for nearly thirteen years, the fact that research they had conducted at the University had yielded patentable inventions to which the University was legally entitled. Bolton, Spireas, and Hygrosol Pharmaceutical Corp. (“Hygrosol”) (collectively, “Defendants”) move to dismiss the claims raised in the Complaint under Federal Rules of Civil Procedure 12(b)(6) and 9(b) for failure to state a claim for which relief may be granted and failure to plead fraud with particularity.
For the reasons set forth below, Defendants’ motions are denied.
I. FACTUAL ALLEGATIONS 1
A. The Parties
Bolton was a professor at St. John’s from 1980 through his retirement in June 1994. (Compl. (Docket Entry # 13) ¶¶ 28, 43.) From 1985 through 1991, Bolton was the chairman of the Department of Pharmacology and Administrative Sciences in the St. John’s College of Pharmacy and Allied Health Professions. (Id. ¶¶ 43-44.) As part of his responsibilities as an employee and faculty member at St. John’s, Bolton conducted research of his own and directed the research of graduate students. (Id. ¶¶ 23-26, 46-47.)
One such graduate student was Spireas, who completed a master’s degree at St. John’s College of Pharmacy and Allied Health Professions in September 1988, and a doctoral degree at St. John’s in February 1993. (Id. ¶¶ 20, 22.) In his capacity as a faculty member, Dr. Bolton advised and directed Spireas in his doctoral dissertation research. (Id. ¶¶ 22-27.)
Spireas’s doctoral dissertation research at St. John’s involved “liquisolid compacts,” also known as “liquisolid systems,” which are terms used to describe the powdered forms of liquid medications. (McElroy Decl. (Docket Entry # 37-1) Ex. H at i-ii.) 2 Liquid lipophilic and water-insoluble solid drugs can be converted to powdered form “by a simple admixture with selected powder excipients referred to as the carrier (e.g., cellulose) and coating (e.g., silica) materials.” (Id. at ii.) This admixture, the “liquisolid system,” enhances the drug’s “release profile” because “the wetting properties and/or surface of the drug available for dissolution are increased.” (Id.) But practical application of this principle had been hampered by “erratic flow and compression properties of the final admixtures.” (Id.)
Spireas theorized that “carrier and coating materials can retain only certain amounts of liquid while at the same time maintaining acceptable flow and compression properties.” (Id.) Spireas confirmed this hypothesis through testing, and created a mathematical model to describe the amount of liquid that a particular liquisolid system could retain while maintaining acceptable flow and compression properties. (Id.) In demonstrating the validity of his model, Spireas produced liquisolid tablets of commercially available drugs, which in some cases exhibited “significantly higher drug release rates than those of their commercial counterparts.” (Id. at ii-iii.)
Beginning in approximately January 1991 Spireas conducted at least some of this research off-campus at facilities owned by a third party, Ciba-Geigy Corporation (“Ciba-Geigy”). (Compl. ¶¶ 78-86.) While St. John’s policies generally prohibited graduate students from conducting research off-campus, (McElroy Deck Ex. F), Bolton helped Spireas obtain special permission from St. John’s allowing him to use Ciba-Geigy’s facilities for his dissertation research (Compl. ¶¶ 78-89). In a February 1991 letter to St. John’s confirming that Ciba-Geigy had given Spireas permission to use its facilities, Ciba-Geigy stated that Spireas had confirmed that “the project will be directed by Dr. Sanford Bolton.” (McElroy Deck Ex. E.) Bolton likewise represented to St. John’s in a March 1991 memorandum that he would be directing Spireas’s research at Ciba-Geigy. (Compl. ¶ 82.) In the acknowledgments section of his dissertation, Spireas thanked his “major advisor, Dr. Sanford Bolton for his invaluable guidance, unlimited encouragement and support during the course of this project,” and Ciba-Geigy, “for offering [him] the unique opportunity to conduct most of this research in their laboratories” and allowing him to use its “ ‘state of the art’ equipment.” (McElroy Deck Ex. H at v.)
Spireas submitted his doctoral dissertation in December 1992 (id. at i), and it was approved by Bolton in January 1993 (id.). Spireas received his doctorate from St. John’s in February 1993 (Compl. ¶ 27). In June 1993, Bolton submitted his notice of retirement to St. John’s, and his teaching duties at the University ended in June 1994. (Id. ¶ 24.)
C. Hygrosol and Defendants’ Efforts to License the Liquisolid Patents
Bolton and Spireas formed Hygrosol in January 1997 and have been its only shareholders from its inception. (Id. ¶¶ 156, 161-62, 313.) Bolton and Spireas assigned all four Liquisolid Patents to Hygrosol, allegedly without fair consideration. (Id. ¶¶ 156-57, 162, 313, 316.) Hygrosol then entered into agreements to license one or more of the Liquisolid Patents to a third party not named as a party in this action. (Id. ¶ 158.) Hygrosol has received at least $100 million in revenue from the licensing agreements, which has been transferred to Bolton and Spireas, and most of which Defendants received after January 2006. (Id. ¶¶ 159-60,162.)
D. The Agreements
St. John’s was a party to four agreements with Bolton and Spireas (collectively, the “Agreements”) which determined the rights and interests of the parties in intellectual property created using St. John’s facilities and other resources. These Agreements were: (1) the Patent Policy; (2) the Bolton Research Agreement; (3) the Spireas Fellowship Agreements; and (4) the Ciba-Geigy Agreement.
1. The Patent Policy
The St. John’s College of Pharmacy and Allied Health Professions had a Patent Policy (the “Patent Policy”) that governed “the ownership of inventions resulting from research conducted by St. John’s faculty and students.”
(Id.
¶ 13.) The Patent Policy “was applicable to all faculty members, researcb/teaching fellows, graduate students, and doctoral students, at the St. John’s College of Pharmacy and Allied Health Professions” from before 1984 to 1994.
(Id.
¶ 15.) The Patent Policy applied to both Bolton and Spireas, both had notice of the Patent Policy, Spireas agreed to the Patent Policy as a condition of his enrollment as a graduate student,
Under the Patent Policy, Bolton and Spireas were contractually obligated to assign to St. John’s
all patentable inventions, discoveries, processes, uses, products, or combinations resulting, in whole or in part, from any of (a) the use of the laboratories or other facilities of [St. John’s], (b) services rendered by faculty to [St. John’s], (c) research conducted by graduate students or doctoral candidates under the direction of [St. John’s] faculty, or (d) any related or predicate research ....
(Id. ¶¶ 14, 46, 51, 75.)
2.The Bolton Research Agreement
In addition to the Patent Policy, Bolton signed an agreement with St. John’s in June 1984 that governed the financial relationship between St. John’s and Bolton regarding his research activities at St. John’s (the “Bolton Research Agreement”). (Id. ¶ 47; Lundin Decl. (Docket Entry ## 36-1 and 36-2) Ex. 3.) 6 The Agreement restated Bolton’s obligation under the Patent Policy to assign to St. John’s all patentable inventions “resulting from research and research related services performed by Bolton at [St. John’s].” (Compl. ¶¶ 47-48; Lundin Decl. Ex. 3.) However, the Agreement contained an additional clause in which the parties agreed that Bolton and St. John’s would split the revenues “derived from the sale or licensing of such inventions, patent applications and patents ... with (a) 30% for St. John’s University and (b) 70% for Dr. Bolton and any student or other person whom Dr. Bolton determines has an interest herein.” (Lundin Decl. Ex. 3.) The Bolton Research Agreement further obligated Bolton to “endeavor with reasonable diligence to secure the necessary patents and use his efforts to introduce such inventions, patent applications, and patents into public use and secure a reasonable revenue therefrom by issuing licenses thereunder or otherwise.” (Lundin Decl. Ex. 3.)
3.The Spireas Fellowship Agreements
Spireas also executed an agreement with St. John’s in April 1988, under which Spireas was granted a paid doctoral fellowship with St. John’s in exchange for agreeing to assign to St. John’s all patentable inventions resulting from his research. (Compl. ¶¶ 76-77.) Spireas signed a second such agreement in April 1989, which continued his doctoral fellowship (collectively the “Spireas Fellowship Agreements”). (Id.)
4.The Cibcir-Geigy Agreement
In 1991, Bolton and Spireas facilitated an agreement between Ciba-Geigy and St. John’s (the “Ciba-Geigy Agreement”) that permitted Spireas to conduct some of his dissertation research using Ciba-Geigy’s facilities while working under Bolton’s supervision. (Id. ¶¶ 78-86.) At Bolton’s and Spireas’s request, Ciba-Geigy sent a letter to St. John’s, including language that reiterated the terms of the Patent Policy. (Id.; McElroy Decl. Ex. E.) St. John’s consented to the arrangement on the condition that Ciba-Geigy acknowledge and not interfere with St. John’s rights to any fruits of the research under applicable St. John’s policies and agreements. (Compl. ¶¶ 78-86.)
To summarize, Plaintiff claims that it entrusted Bolton and Spireas with the resources they needed to make the scientific discoveries from which the Liquisolid Patents are derived. Moreover, St. John’s support was expressly conditioned on Bolton’s and Spireas’s assent to this bargain: resources for intellectual property rights. But neither Bolton nor Spireas ever informed St. John’s that their research had resulted in patentable inventions, the issuance of the Liquisolid Patents, or royalties derived from licensing the Liquisolid Patents. (Id. ¶¶ 115-54, 163-65.) In fact, shortly after Spireas graduated from St. John’s, and shortly before Bolton and Spireas filed their first patent application, Bolton resigned from the University. (Id. ¶ 155.) Plaintiff alleges that Bolton left the University because he believed it would be easier to conceal the success of his research from St. John’s if he was no longer an employee. (Id.) Plaintiff further alleges that Bolton’s and Spireas’s purpose in forming Hygrosol and assigning the Liquisolid Patents to it was to prevent Plaintiff from later asserting its contractual rights to the ownership of the Liquisolid Patents and its share of the royalties derived from licensing them. (Id. ¶¶ 157-62, 314-316.)
II. DISCUSSION
A. Legal Standard Applicable to the Motions to Dismiss
1. General Standard under Rule 12(b)(6)
The purpose of a motion to dismiss for failure to state a claim under Rule 12(b)(6) is to test the legal sufficiency of a plaintiffs claims for relief.
Patane v. Clark,
In deciding a motion to dismiss under Rule 12(b)(6), the court may, at its discretion, consider matters of which judicial notice may be taken, as well as documents extrinsic to the complaint where a plaintiff “relies heavily upon [the documents] terms and effect, [thus] rendering] the document integral to the complaint.”
Chambers v. Time Warner, Inc.,
2. Standard for Assessing Statute of Limitations Defense under Rule 12(b)(6)
Under New York law, the statute of limitations is an affirmative defense, and the defendant bears the burden of proving
Therefore, on a motion to dismiss under Rule 12(b)(6), a claim may be dismissed as time-barred under the statute of limitations only if the factual allegations in the complaint clearly show that the claim is untimely.
Harris v. City of New York,
B. Plaintiffs Claims and the Motions to Dismiss
Plaintiffs 61 page Complaint states 15 overlapping causes of action in its 318 numbered paragraphs. Those causes of action can be grouped into nine categories: (1) Bolton and Spireas violated their contractual obligations under the Agreements by failing to assign the Liquisolid Patents to the University; and, (2) in the case of Bolton, by failing to share with the University revenues he received from licensing the Liquisolid Patents (id. ¶¶ 198-250); (3) Bolton and Spireas tortiously breached their fiduciary duties to the University (id. ¶¶ 251-59, 268-75); (4) Bolton and Spireas fraudulently failed to disclose the value and patentability of their research at St. John’s (id. ¶¶ 178-97); (5) Spireas aided and abetted Bolton’s breaches of his fiduciary duty to St. John’s (id. ¶¶ 260-67); (6) Spireas tortiously interfered with Bolton’s contractual obligations to St. John’s (id. ¶¶ 276-82); (7) Bolton’s and Spireas’s assignments of the Liquisolid Patents to Hygrosol were fraudulent conveyances intended to prevent St. John’s from asserting its rights to the Liquisolid Patents under the Agreements (id. ¶¶ 312-18); (8) Defendants have been unjustly enriched at the expense of St. John’s (id. ¶¶ 283-94); and (9) Defendants have converted property to which St. John’s has superior rights of possession (id. ¶¶ 295-305). Plaintiff seeks equitable relief in the form of an order of specific performance for Defendants to assign the Liquisolid Patents to St. John’s, and an order directing an equitable accounting of the Defendants’ books and assets to determine the revenues obtained from the Liquisolid Patents. Plaintiff also seeks compensatory and punitive monetary damages.
In their two motions to dismiss, Defendants generally assert two types of defenses: (1) Plaintiffs allegations of fact are insufficient to state a claim for relief under Federal Rule of Civil Procedure 12(b)(6) and, in some cases, Rule 9(b); and (2) Plaintiffs claims are untimely under the relevant statutes of limitations. Plaintiff responds that its allegations of fact entitle it to equitable tolling of the statutes of limitations. (Opp. at 41-43.)
C. Breach of Contract
Plaintiff alleges that Bolton and Spireas breached two independent contractual obligations: (1) Bolton’s and Spireas’s obligation to assign the Liquisolid Patents to St. John’s; and (2) their obligation to share the Liquisolid Patents’ licensing royalties with St. John’s. Under New York law, “[t]o make out a viable claim for breach of contract a complaint need only allege (1) the existence of an agreement, (2) adequate performance of the contract by the plaintiff, (3) breach of contract by the defendant, and (4) damages.”
Eternity Global Master Fund Ltd. v. Morgan Guaranty Trust Co. of N.Y.,
1. Breach of the Assignment Obligations
Defendants argue that Plaintiff has failed to sufficiently allege that Bolton and Spireas breached an agreement to assign patentable inventions to St. John’s.
(See
Spireas’s and Hygrosol’s Mem. (“Spireas Mem.”) (Docket Entry # 41) at 5-7.) St. John’s has pleaded the existence of Bolton’s and Spireas’s contractual duty to assign patentable inventions derived “in whole or in part” from research conducted at St. John’s under the Patent Policy and the other Agreements. St. John’s has also pleaded that it performed its obligations under the Agreements by employing Bolton and Spireas, enrolling Spireas as a graduate student, and giving both Bolton and Spireas the benefit of its resources. St. John’s has further pleaded that the Liquisolid Patents are based on inventions derived “in whole or in part” from research performed at St. John’s and subject to the Agreements, and that Bolton and Spireas have not assigned the Liquisolid Patents to St. John’s. Finally, St. John’s has pleaded that it has been damaged be
Bolton argues that “the Complaint does not contain any plausible allegation that Dr. Bolton conducted research at [St. John’s] relating to the patented invention; he did not.” (Bolton’s Reply Mem. (“Bolton Reply”) (Docket Entry #38) at 6; Bolton’s Mem. (“Bolton Mem.”) (Docket Entry # 36-3) at 17-18.) This argument is without merit. In its brief and in side-by-side comparisons of portions of the initial '834 Patent with sections of the dissertation (McElroy Decl. Ex. G), St. John’s points out that significant material in the '834 Patent is literally copied from Spireas’s dissertation (Opp. at 3-4). Furthermore, Spireas was a graduate student working under Bolton’s direction when Spireas conducted the research presented in the dissertation, and Bolton assisted Spireas in obtaining St. John’s permission to do some of the research off campus at Ciba-Geigy with the express understanding that such off-campus work would not impair St. John’s rights to the fruits of that research.
Spireas argues in the alternative, and for the first time in his Reply, that even if he was obligated to assign the '834 and '550 Patents, the '337 and '339 Patents are unrelated to them and the “contractual duty to assign or fiduciary duty to disclose ... the invention claimed in the '834 and '550 patents ... could not, as a matter of law, extend to the '337 and '339 Patents.” (Spireas’s and Hygrosol’s Reply Mem. (“Spireas Reply”) (Docket Entry # 42) at 8-9.) Spireas contends that the '337 and '339 Patents, which are continuations-in-part (“CIPs”) of the '834 and '550 Patents, are legally unrelated to the '834 and '550 Patents, simply because they include “additional subject matter not present in earlier filed patents.” (Spireas Reply at 9-10 (emphasis in original).)
Spireas’s argument fails for two reasons. First, St. John’s has alleged that the '337 and '339 Patents were derived in whole or in part from research conducted at St. John’s. Spireas’s argument that the '337 and '339 Patents are unrelated to the '834 and '550 Patents simply does not respond to this allegation. Second, Spireas’s claim that they CIPs are legally unrelated to the '834 and '550 Patents misstates the law. While a CIP must include subject matter not contained in the earlier patent, it must also contain subject matter contained in the earlier patent. By definition, a CIP “is an application filed during the lifetime of an earlier nonprovisional application,
repeating some substantial portion or all of the earlier nonprovisional application
and adding matter not disclosed in the said earlier nonprovisional application.” Manual of Patent Examining Procedure (“MPEP”) § 201.08 (8th ed., Rev. 8, July 2010) (emphasis added). The relevant question for purposes of St. John’s claims is whether the subject matter of the '337 and '339 Patents include research derived in whole or in part from research conducted at St. John’s. If St. John’s is entitled to assignment of the '834 and '550 patents because their subject matter discloses an invention that is the product, in whole or in part, of research conducted at St. John’s, it is possible that the “substantial portion” of the '834 and '550 Patents contained in the '337 and '339 Patents is also derivative of research performed at St. John’s. Drawing all reasonable inferences in favor of St. John’s, the possibility that the '337 and '339 Patents are unrelated to the '834 and '550 Patents is plainly insufficient for the court to conclude on a motion to dismiss that the '337 and '339 Patents are not
Bolton also argues that because he was not listed as an inventor of the '339 Patent St. John’s has no breach of contract or fiduciary duty claim against him for his actions in relation to that patent.
9
(Bolton Mem. at 1.) St. John’s alleged contract rights relate to patentable inventions or discoveries derived in whole or in part from research conducted at St. John’s— not just patents. Therefore, it is irrelevant whether Bolton was listed as an inventor on the face of the 339 Patent.
HIF Bio, Inc. v. Yung Shin Pharmaceuticals Indus. Co., Ltd.,
2. Breach of the Revenue-Sharing Obligation
Defendants also argue that Plaintiff has failed to sufficiently allege that Bolton and Spireas breached an agreement to share licensing royalties with St. John’s. The terms of the Bolton Research Agreement impose express contractual duties on St. John’s and Bolton to share the revenues derived from the sale or licensing of inventions or patents resulting in whole or in part from his research related services at St. John’s. (Lundin Decl. Ex. 3.) St. John’s has pleaded that it performed its obligations under the Bolton Research Agreement by employing Bolton and giving Bolton the benefit of its resources. St. John’s has further pleaded: that the Liquisolid Patents are based on inventions derived in whole or in part from Bolton’s research related services at St. John’s; that Bolton has obtained royalties from licensing the Liquisolid Patents; and that Bolton has not shared any of those licensing revenues with St. John’s. Finally, St. John’s has pleaded that it has been damaged because it has not received its share of royalty revenues. Under New York law, St. John’s has sufficiently alleged that Bolton breached his contractual obligation under the Bolton Research Agreement to share patent-licensing royalties with it.
Bolton argues that St. John’s rights to revenue sharing can only be derivative of St. John’s right to assignment of the Liquisolid Patents, and are thus dependent on St. John’s ability to establish its claims for breach of the patent-assignment obligation. (Bolton Mem. at 8-9.) Similarly, Bolton argues that the revenue-sharing provision of the Bolton Research Agreement must be read in conjunction with the assignment provision as a residual protection of
only
Bolton’s interest in the royalty revenues. (Bolton Reply at 1-3.) Bolton contends that because St. John’s was entitled to full ownership of the patent, including the right to all licensing royalties, the parties contemplated only that St. John’s would share revenues with Bolton, not that
The revenue-sharing term in the Bolton Research Agreement was a separate contractual duty that applied independent of Bolton’s performance of the assignment obligation. Because the court interprets the assignment obligation under the Agreements to impose a duty of future performance on Bolton and Spireas, rather than effect an automatic assignment, (see infra Part II.C.4.a), it is reasonable to infer that St. John’s and Bolton anticipated there might be a gap between the issuance of a patent to Bolton and the subsequent assignment of the patent to St. John’s. Drawing all reasonable inferences in favor of Plaintiff, the court interprets the revenue-sharing provision to protect both St. John’s and Bolton’s interests in receiving the stated revenues — St. John’s share prior to assignment, and Bolton’s share following assignment. Indeed, the revenue-sharing term does not specifically state which party is obligated to make the royalty payments, it states: “It is further understood and agreed that a percentage of the revenue derived from the sale or licensing of such inventions, patent application and patents, shall be shared with (a) 30% for St. John’s University and (b) 70% for Dr. Bolton, and any student or other person whom Dr. Bolton determines has an interest herein, their heirs, assigns and personal representatives.” (Lundin Decl. Ex. 3.) Bolton’s obligation to share licensing royalties with St. John’s is not dependent on St. John’s right to have Bolton assign the Liquisolid Patents to it.
While the Bolton Research Agreement clearly obligates Bolton to share royalty payments with St. John’s, Plaintiff has not pleaded the existence of a similar contract term independently obligating Spireas to share royalty revenues with St. John’s. Furthermore, St. John’s does not allege facts sufficient to infer that Spireas had an independent contractual duty under the Patent Policy, Spireas Fellowship Agreements, or Ciba-Geigy Agreement to share royalty revenues with St. John’s. To the extent Spireas is under an obligation to share royalties with St. John’s, that obligation is derivative of St. John’s right to assignment of Spireas’s interest in the Liquisolid Patents.
3. Public Policy Arguments Against Enforceability
Defendants argue, in the alternative, that Plaintiffs interpretation of the language in the Agreements giving Plaintiff rights to all inventions resulting “in whole or in part” from research conducted at St. John’s is so broad as to constitute an open-ended assignment of all an inventor’s future inventions, and are unenforceable under public policy principles prohibiting a “mortgage on a man’s brain.” (Spireas Mem. at 7.) This argument is without merit. As explained in case law setting forth this ancient doctrine, a patent assignment agreement is an unenforceable “mortgage on a man’s brain” when it is “[a] naked assignment or agreement to assign, in gross, a man’s future labors as an author or inventor,” including those as yet unknown.
Aspinwall Manufacturing Co. v. Gill,
While it may be that the “in whole or in part” language in St. John’s assignment provision is susceptible of potentially impermissible interpretations that would allow St. John’s to assert ownership over inventions not substantially related to research performed at St. John’s,
see, e.g., American Cone and Wafer Co. v. Consolidated Wafer Co.,
Advancing a somewhat similar argument, Spireas contends that courts have narrowly interpreted patent policies to apply only to patent applications filed while the researcher was employed or enrolled at the university. (Spireas Mem. at 5-6; Bolton Mem. at 13 n. 7.) Here, the applications for the Liquisolid Patents were not filed until after Bolton and Spireas left St. John’s. Spireas cites
Fenn v. Yale University,
Furthermore, the court perceives no reason why it should be the first to endorse Spireas’s public policy argument. Spireas’s argument, that patent policies are only enforceable with respect to patents applied for during a researcher’s affiliation with the university, would create undesirable incentives for those engaged in productive research to abruptly end their work and leave the university at the first hint that they had made a profitable discovery — or worse, to conceal and hoard scientific discoveries for later exploitation. The court perceives no public policy concern with permitting a university to enforce its rights to intellectual property when, as is the case here, those intellectual property rights are implicated by patent applications filed by its former employees or students after they leave the university.
Defendants’ most serious challenge to the two categories of contract claims is that they are time-barred under the relevant New York statutes of limitations. In New York, an action to enforce a contractual obligation is subject to a six-year limitations period. N.Y. C.P.L.R. § 213(2). “Under New York law, a cause of action for breach of contract accrues and the statute of limitations commences when the contract is breached.”
T & N PLC v. Fred S. James & Co. of New York, Inc.,
a. Accrual of Claim for Breach of the Assignment Obligations
St. John’s repeatedly alleges that Bolton and Spireas had “agreed” or were “obligated” or “required” to assign the Liquisolid Patents, implying that the Agreements contemplated future performance by Bolton and Spireas in assigning their inventions to the University. In
Board of Trustees of the Leland Stanford Junior University v. Roche Molecular Systems, Inc.,
The first act alleged in the Complaint which clearly breached Bolton’s and Spireas’s assignment obligation was their assignment of the Liquisolid Patents to Hygrosol. The assignment of a patent divests the assignor of any ownership stake in the patent and leaves him with nothing more to assign, thus negating any future assignment to a third party.
Stanford,
The Complaint does not allege on what dates Bolton and Spireas owed St. John’s duties of performance under the Agreements, such that their failure to assign the Liquisolid Patents on those dates would constitute a breach of their promises to assign; but it does allege a breach of those Agreements. As the Federal Circuit noted in
Stanford,
a researcher’s agreement to assign his future interests in a patent may not necessarily specify the time for the researcher’s performance. The patent agreement at issue in that case provided that the researcher “agreed only to assign his invention rights to Stanford at an undetermined time.”
Stanford,
Under New York law “[e]ven though a contract fixes no time for performance, if not void for uncertainty, an agreement is implied that the act shall be done within a reasonable time.”
City of New York v. New York Cent. R.R. Co.,
It is clear that obtaining patent protection for subject inventions was the event of greatest importance to the parties, and the focus of the Agreements. The Agreements contemplated that Bolton and Spireas would engage in research oyer an extended period of time, and could conceivably make several discoveries yielding patentable inventions. The determination how to define a particular invention, and whether it was a “patentable invention” subject to the Agreements, would not necessarily become clear until the parties decided to seek patent protection for it. Thus, while St. John’s might have demand
Under New York law “knowledge of the occurrence of the wrong on the part of the plaintiff is not necessary to start the Statute of Limitations running in a contract action.”
Ely-Cruikshank Co., Inc. v. Bank of Montreal,
b. Accrual of Claim for Breach of the Revenue-Sharing Obligations
Bolton’s obligation to share licensing revenues with St. John’s, as alleged, constitutes a contract requiring continuing performance over a period of time, with each successive breach subject to its own limitations period.
See Guilbert v. Gardner,
D. Fiduciary Duty
1. Allegation of a Fiduciary Relationship
Plaintiff alleges that Bolton and Spireas owed it a fiduciary duty to disclose the
In New York, the existence of a fiduciary relationship is determined on a case-by-case basis. “A fiduciary relation exists between two persons when one of them is under a duty to act or to give advice for the benefit of the other upon matters within the scope of the relation.”
Mandelblatt v. Devon Stores, Inc.,
In beginning this relationship-specific inquiry, New York courts look first to whether there is a contractual relationship between the parties. “[W]here parties have entered into a contract, courts look to that agreement ‘to discover ... the nexus of [the parties’] relationship and the particular contractual expression establishing the parties’ interdependency.’ ”
EBC I, Inc. v. Goldman Sachs & Co.,
5 N.Y.3d II, 19-20,
But the court’s inquiry does not end with an examination of the parties’ written agreements. “[I]t is not mandatory that a fiduciary relationship be formalized in writing, and any inquiry into whether such obligation exists is necessarily fact-specific to the particular case. Beyond what may be memorialized in writing, a court will look to whether a party reposed confidence in another and reasonably relied on the other’s superior expertise or knowledge.”
Wiener,
The terms of the parties’ written Agreements, as alleged by Plaintiff, provide the court’s starting point. Plaintiff has alleged that the Agreements implicitly created a relationship of trust and confidence between St. John’s and Bolton and Spireas by making St. John’s dependent on the two to assess the value of their research and notify St. John’s if their work produced a patentable invention. The
The parties’ course of conduct and the nature of their relationship compel the same conclusion. In a case presenting similar issues,
Fenn,
The same is true here. Bolton and Spireas were entrusted with St. John’s resources and the autonomy and discretion to use those resources, because they possessed the special knowledge and expertise required to exploit those resources through useful research that might result in patentable discoveries. St. John’s further entrusted Bolton with the responsibility of overseeing Spireas’s research as his dissertation research advisor, and it is reasonable to infer from the Complaint that Spireas was accountable largely to Bolton alone. It is also true, however, that the same special knowledge and expertise that made it worthwhile for St. John’s to support Bolton and Spireas’s research also left St. John’s dependent on them to determine whether their research had succeeded in producing a patentable invention. To paraphrase Fenn: Bolton and Spireas knew more about the value and patentability of inventions they developed than anyone else, and St. John’s necessarily and reasonably relied on their expertise in evaluating such inventions. See id. Indeed, it is difficult to imagine how St. John’s would have been able to independently determine the patentability and value of Bolton’s and Spireas’s research without their affirmative disclosure of material information relating to it.
On the facts alleged, St. John’s was vulnerable to Bolton’s and Spireas’s abuse of their positions of trust which they willingly solicited and accepted, Bolton and Spireas were empowered by this relative superiority in relation to their research, and St. John’s was prevented from effectively protecting its interests because of Defendants’ empowerment.
See Atlantis Information Technology,
2. Relationship Between Students or Professors and Universities
Defendants contend that as a matter of law, neither employees nor students can be fiduciaries of a university. (Spireas Mem.
Spireas cites
Moy v. Adelphi Institute,
Spireas also relies on
University of Pittsburgh v. Townsend,
3. Limitations Period Applicable to Fiduciary Breach
Ordinarily, a tort claim for a breach of fiduciary duty accrues on the date the fiduciary breaches his duty,
Kaufman v. Cohen,
The parties dispute the date on which any fiduciary relationship might have been terminated. 12 Bolton and Spireas argue that their separation from the University ended any fiduciary relationship they might have had with St. John’s, and commenced the running of the statute of limitations. (Spireas Reply at 2; Bolton Mem. 12-13.) St. John’s contends that even after Bolton and Spireas left the University, their fiduciary duties to St. John’s, with respect to the research they had conducted there, continued. (Opp. at 24-25.)
Bolton and Spireas ask this court to treat this case like any other in which an employee, who is also a fiduciary of his employer, leaves his job and thereby terminates the fiduciary relationship. However, this case is not analogous to those, cited by Bolton and Spireas, in which an employee, typically an officer or director of a corporation, leaves his position and competes with his former employer.
See, e.g., Manley v. AmBase Corp.,
In this case, the fiduciary duties alleged by St. John’s arose not merely from Defendants’ employment or enrollment at St. John’s, but principally from their direction of a research venture in which St. John’s had a continuing financial interest. The closer analogy is to the duties of fiduciaries with respect to “corporate opportunities” in which their principal has a “tangible expectancy.”
See Alexander & Alexander of New York, Inc. v. Fritzen,
While Bolton and Spireas were not literally working under a duty to acquire patentable inventions for St. John’s, St. John’s did have a tangible expectancy, under the Agreements, in any patentable inventions that resulted from their research. It is irrelevant that Bolton and Spireas were no longer affiliated with St. John’s when they patented the inventions because their duties in relation to the inventions arose when they conducted the research on which the inventions were based while they were at St. John’s.
Plaintiff has alleged facts sufficient to establish that the fiduciary relationship alleged in the Complaint did not terminate when Bolton and Spireas left the University, and existed until Bolton and Spireas openly repudiated St. John’s demands for performance of the Agreements in November 2008. (Compl. ¶¶ 300-301.) Therefore, Plaintiffs claim for breach of fiduciary duty falls well within the six-year limitations period ordinarily applicable to tort claims for breach of fiduciary duty. Thus the claims for Bolton and Spireas’s breach of their fiduciary duties are timely. 13
4. Equitable Action for Accounting
Defendants argued that Plaintiffs accounting claim must be dismissed because Defendants are not fiduciaries of Plaintiff. (Bolton Mem. 18; Spireas Mem. at 22.) Because St. John’s has adequately alleged the existence of a fiduciary relationship with Bolton and Spireas this objection is without merit.
14
Kastle v. Steibel,
E. Spireas’s Vicarious Liability for Bolton’s Breaches of Fiduciary Duty and Contract
Plaintiff alleges that Spireas is liable for: (1) aiding and abetting Bolton’s breach of
1. Aiding and Abetting Breach of Fiduciary Duty
“The elements of a cause of action for participation in a breach of fiduciary duty are: breach by a fiduciary of a duty owed to plaintiff; defendant’s knowing participation in the breach; and damages.”
SCS Commc’ns, Inc. v. Herrick Co., Inc.,
The statute of limitations applicable to a claim that the defendant aided and abetted another’s breach of his fiduciary duties is subject to the same limitations period applicable to the underlying breach of fiduciary duty.
Balta v. Ayco Company, LP,
2. Tortious Interference with Contract
“Under New York law, the elements of a tortious interference with contract claim are: (a) that a valid contract exists; (b) that a ‘third party’ had knowledge of the contract; (c) that the third party intentionally and improperly procured the breach of the contract; and (d) that the breach resulted in damage to the plaintiff.”
Albert v. Loksen,
Plaintiff has stated claims for breach of contract against Bolton, and that these breaches harmed Plaintiff. While Plaintiff has the ultimate burden of proving by a preponderance of the evidence that Spireas had actual knowledge of Bolton’s contractual obligations to St. John’s,
Furthermore, it is reasonable to infer from the Complaint that Spireas intentionally procured this breach. An actor intentionally procures a breach of a third party’s contract even where the breach “is incidental to the actor’s independent purpose and desire but known to him to be a necessary consequence of his action.” Restatement (Second) of Torts § 766 cmt. j. Plaintiffs case is largely premised on the theory that Bolton and Spireas intentionally failed to disclose the value of their research to St. John’s in order to keep the Liquisolid Patents and licensing royalties for themselves. Any royalties Bolton might have shared with St. John’s, or any assignment Bolton might have made of his interests in the Liquisolid Patents, would have been glaring evidence of Defendants’ fraud that would have alerted St. John’s to the existence of its claims against Spireas. It is reasonable to infer that Spireas knew that Bolton’s breach of the Agreements was necessary to the fulfillment of his scheme to retain his interests in the Liquisolid Patents and the licensing royalties, even if Bolton’s breach of the Agreements was incidental to that scheme.
It is also reasonable to infer that Spireas’s failures to perform the contractual duties he owed to St. John’s, as well as his assignment of his interests in the Liquisolid Patents to Hygrosol were a “but for” cause of Bolton’s breach. The inducement causing the breach “may be any conduct conveying to the third person the actor’s desire to influence him not to deal with the other.... [I]t may be the promise of a benefit to the third person if he will refrain from dealing with the other.” Restatement (Second) of Torts § 766 cmt. k. Had Spireas complied with his fiduciary and contractual duties to disclose the patentability of the inventions and assign his interest in the Liquisolid Patents to St. John’s, St. John’s would have been alerted to Bolton’s interests in the Liquisolid Patents and Bolton would have had little choice but to comply with his contractual obligations to assign them and share royalty revenues with St. John’s. But for Spireas’s actions in breaching his contractual
Plaintiff’s cause of action for tortious interference with contract is subject to the three-year limitations period imposed by N.Y. C.P.L.R. § 214(4). Under New York law a tortious interference with contract claim accrues when the tort is completed — ordinarily when Plaintiff sustains damages.
Kronos, Inc. v. AVX Corp.,
Plaintiff did not sustain damages as a result of Spireas’s interference with Bolton’s assignment obligation until Bolton assigned his interests in the Liquisolid Patents to Hygrosol and St. John’s was no longer capable of obtaining the benefit of its bargain — title to the Liquisolid Patents — from Bolton. For the reasons explained supra Part II.C.4.a, the court cannot conclude that the assignments occurred before they were registered with the PTO on October 12, 2006, a date clearly within the three-year limitations period. Plaintiffs claims against Spireas for interference with Bolton’s assignment obligation are timely.
Plaintiffs tortious interference claims in respect of Bolton’s breach of his contractual revenue-sharing obligation accrued when Bolton received royalties and failed to share them with Plaintiff, and are timely insofar as they relate to royalties received by Bolton within three years of the commencement of this action. Any claims to royalties received outside of the limitations period are untimely absent Plaintiffs ability to establish that it is entitled to equitable tolling of the statute of limitations. See infra Part II.I.2.
F. Fraud
Plaintiff alleges two claims that sound in fraud. The Complaint includes a tort claim against Bolton and Spireas for fraudulent concealment, and an equitable fraudulent conveyance claim against Bolton, Spireas, and Hygrosol.
1. Fraudulent Concealment
Plaintiffs theory of fraudulent concealment is that Bolton’s and Spireas’s failures to disclose material facts relating to the value and patentability of the inventions and the revenues obtained therefrom constituted affirmative misrepresentations to St. John’s that no patentable inventions existed. (Opp. at 17, 25-29.) Defendants respond that Plaintiff has: (1) failed to state a cause of action for fraudulent concealment by failing to allege any affirmative act concealing the existence of the Liquisolid Patents; (2) failed to plead fraud with particularity; and (3) failed to allege facts creating a strong inference of fraudulent intent. (Bolton Mem. at 16-17; Spireas Mem. at 14-15, 23-24.)
“It is well settled that when there is a duty to speak, silence may very well constitute fraudulent concealment, which is itself the equivalent of affirmative
Rule 9(b) requires that a plaintiff pleading fraud “state with particularity the circumstances constituting fraud.... ” Fed.R.Civ.P. 9(b);
see also Solow v. Stone,
In the case of fraudulent concealment or omission, where the plaintiff is unable to specify the time and place because no act occurred, the complaint must still allege: (1) what the omissions were; (2) the person responsible for the failure to disclose; (3) the context of the omissions and the manner in which they misled the plaintiff; and (4) what the defendant obtained through the fraud.
Watts v. Jackson Hewitt Tax Serv. Inc.,
Under New York law there are two types of fraud: “actual fraud,” which “involves the element of deceit practiced upon the party defrauded,”
Nasaba Corp.,
Under Rule 9(b), Plaintiff need not allege intent with particularity, but Plaintiffs factual allegations must create a strong inference of fraudulent intent. “The requisite ‘strong inference’ of fraud may be established either (a) by alleging facts to show that defendants had both motive and opportunity to commit fraud, or (b) by alleging facts that constitute strong circumstantial evidence of conscious misbehavior or recklessness.”
Lerner v. Fleet Bank, N.A.,
2. Fraudulent Conveyance
Plaintiff alleges that Bolton’s and Spireas’s assignments of the Liquisolid Patents to Hygrosol were fraudulent conveyances in violation of New York law. Specifically, Plaintiff claims that Bolton and Spireas assigned the Liquisolid Patents to Hygrosol knowing that they had contractual duties to assign them to St. John’s, and with the intent that the assignments to Hygrosol would render them incapable of performing their contractual duties. (Opp. at 35-36.) Defendants respond that Plaintiff has failed to plead fraudulent intent with particularity. (Bolton Mem. at 15-16; Spireas Mem. at 23.)
Under New York law, “[e]very conveyance made and every obligation incurred with actual intent, as distinguished from intent presumed in law, to hinder, delay, or defraud either present or future creditors, is fraudulent as to both present and future creditors.” N.Y. Debt. & Cred. Law § 276 (“DCL § 276”). “[A] transfer made with actual intent to hinder, delay, or defraud present or future creditors is fraudulent as to such creditors, regardless of whether the debtor receives fair consideration for its property.”
HBE Leasing Corp. v. Frank,
Actual intent to hinder, delay, or defraud must be pleaded with specificity under Rule 9(b).
In re Sharp Int’l Corp.,
First, Plaintiff has alleged that Bolton and Spireas received grossly inadequate consideration in exchange for assigning the Liquisolid Patents to Hygrosol. In a related context, courts assess the fairness of consideration supporting a transfer under DCL §§ 272 and 273 by measuring the value of the economic benefits the debtor received from the transaction against the value of the property transferred.
HBE Leasing,
Second, the relationship between Bolton and Spireas as transferors, and Hygrosol as transferee, was extremely close — Plaintiff has alleged that Bolton and Spireas incorporated and were the sole shareholders of the company at the time of the transfer. Third, even after transferring the Liquisolid Patents to Hygrosol, Plaintiff alleges that Bolton and Spireas have retained full control over the Liquisolid Patents, and enjoy all the benefits of patent ownership through their complete control over Hygrosol’s affairs. 16 As alleged in the Complaint, the royalties received by Hygrosol under its patent licensing agreements, the most important benefit of patent ownership, simply pass through the corporation to Bolton and Spireas.
Fourth, there was considerable secrecy in the transfer of Bolton’s and Spireas’s ownership interests in the Liquisolid Patents. Under patent law an assignee may perfect its ownership interest in a patent by publicly recording the assignment with the PTO. See 35 U.S.C. § 261. 'Although the PTO’s records indicate that Hygrosol represented to the PTO that Bolton and Spireas assigned the Liquisolid Patents to it in 1998, the transfer was not publicly recorded with the PTO until 2006. 17 Assuming that the representations to the PTO were accurate and the assignments occurred in 1998, the implication is that Hygrosol elected not to avail itself of the legal protections afforded by recording the assignments for nearly eight years. Until the patent assignments were recorded with the PTO there was no public record of the assignments, and the only third party with knowledge of the assignments was the third party to which Hygrosol licensed the Liquisolid Patents.
Under the circumstances, Plaintiffs allegations of fact support a strong inference that Bolton and Spireas assigned the Liquisolid Patents to Hygrosol with the intent to defraud Plaintiff. Therefore, Plaintiff has' alleged facts from which it can reasonably be inferred that the Liquisolid Patent assignments were fraudulent conveyances under DCL § 276.
G. Conversion
In New York, “[conversion is the unauthorized assumption and exercise of the right of ownership over goods belonging to another to the exclusion of the owner’s rights.”
State of New York v. Seventh Regiment Fund, Inc.,
Plaintiff alleges that it has a right to possession of the Liquisolid Patents under the Agreements, and that Defendants have exercised dominion over the property in derogation of those rights. Bolton and Spireas argue that the conversion claim against them merely duplicates the Plaintiffs contract claims because Plaintiff has failed to allege wrongful behavior independent of their alleged breaches of contract which would entitle Plaintiff to special damages. (Spireas Mem. at 21-22.) All Defendants object that Plaintiffs conversion claims are untimely under the statute of limitations. (Spireas Mem. at 21; Bolton Mem. at 10-11.)
1. Availability of Special Damages
Under New York law, “[i]t is a well-established principle that a simple breach of contract is not to be considered a tort unless a legal duty independent of the contract itself has been violated.”
Clark-Fitzpatrick, Inc. v. Long Island R.R. Co.,
The conversion claim is not duplicative of St. John’s contract claims against Bolton and Spireas because success on the conversion claim may entitle Plaintiff to special damages. Punitive damages “may be recovered for an act of conversion where the circumstances establish that the conversion was accomplished by malice or reckless or willful disregard of the plaintiffs right.”
Ashare v. Mirkin, Bawe, Saltzstein & Gordon, P.C.,
It is reasonable to infer from the facts alleged in the Complaint that Bolton and Spireas knew of Plaintiffs rights and deliberately and intentionally interfered with them.
See Ashare,
2. Statute of Limitations
New York applies a three-year statute of limitations for conversion. N.Y. C.P.L.R. § 214(3).
“A
cause of action for conversion accrues when all of the facts necessary to sustain the cause of action have occurred, so that a party could obtain relief in court.”
Seventh Regiment,
Bolton and Spireas argue that by dealing openly with the Liquisolid Patents as their own — ie., by filing the patent applications, obtaining the Liquisolid Patents in their names as inventors, and subsequently assigning them to Hygrosol — they interfered with St. John’s rights to the Liquisolid Patents and the statute of limitations began to run. (Bolton Mem. at 10-11; Spireas Mem. at 21.) Bolton,argues that because these events occurred outside the limitations period, Plaintiffs claims are time-barred. (Id.)
From the allegations in the Complaint, Bolton’s and Spireas’s initial ownership and possession of the Liquisolid Patents was not wrongful. Under federal law a patent is issued to the inventors, who are the owners of the patent in the first instance, unless and until they assign it.
18
St. John’s allegations as to the patent-assignment terms in the Agreements — the source of Plaintiffs right of possession— demonstrate that the parties contemplated that St. John’s would obtain ownership of
Bolton and Spireas argue that Plaintiffs cause of action for conversion accrued at least by the time they assigned the Liquisolid Patents to Hygrosol. (Bolton Mem. at 10.) Plaintiff responds that a person who comes lawfully into possession of personalty does not convert it until he refuses a demand for its return from the true owner. (Opp. at 40.) Plaintiffs argument, however, states only half the law. The New York Court of Appeals has consistently held that a cause of action for conversion against a bona fide purchaser accrues
either
after demand and refusal
or
earlier, when a bona fide purchaser openly takes action in respect of the property which is inconsistent with the true owner’s rights.
See, e.g., MacDonnell,
Bolton’s and Spireas’s assignment of the Liquisolid Patents to Hygrosol was an exercise of dominion over the Liquisolid Patents inconsistent with St. John’s rights, and was an affirmative act constituting conversion. However, on the facts alleged the court cannot conclude that the assignments occurred before they were regis
If Hygrosol were a bona fide purchaser of the Liquisolid Patents, Plaintiffs claims for conversion would not accrue against Hygrosol until it refused Plaintiffs demands for assignment of the Liquisolid Patents, or Hygrosol openly exercised dominion and control over the Liquisolid Patents to the exclusion of St. John’s rights. Plaintiff demanded assignment of the Liquisolid Patents from Hygrosol by making the demand to Bolton and Spireas, its sole shareholders, in November 2008. However, according to the Complaint, Hygrosol took at least two other acts incompatible with Plaintiffs rights in the Liquisolid Patents before St. John’s demand and Hygrosol’s refusal.
Hygrosol recorded the assignments with the PTO on October 12, 2006,
20
an open expression of dominion incompatible with Plaintiffs rights to the Liquisolid Patents, but a date still within the three-year limitations period. Even if the court assumes that the assignments to Hygrosol actually occurred earlier than the date of their recordation,
21
the mere assignment of the Liquisolid Patents by Bolton and Spireas to an entity of their own creation were simply “private paper transactions” which would be insufficient to constitute a conversion by Hygrosol until it recorded them in 2006.
Seventh Regiment,
Plaintiff also alleges that Hygrosol commercially exploited the Liquisolid Patents by licensing them to a third party. Under New York law, the commercial exploitation of personal property is an interference with the rights of the true owner sufficient to constitute conversion.
Id.
at 260,
Plaintiff alleges that Defendants have been unjustly enriched at its expense, and that it is entitled, in equity and good conscience, to the Liquisolid Patents and a share of the resulting royalty payments. Defendants (1) attack the sufficiency of the unjust enrichment claim; (2) argue that it impermissibly duplicates Plaintiffs contract claims; and (3) argue that the claim is untimely under the relevant statute of limitations.
1. Sufficiency of Unjust Enrichment Claim
To make out a claim for unjust enrichment, a plaintiff must establish, “(1) that the defendant benefitted; (2) at the plaintiffs expense; and (3) that equity and good conscience require restitution.”
Beth Israel Medical Ctr. v. Horizon Blue Cross and Blue Shield of New Jersey, Inc.,
Bolton and Spireas argue that St. John’s has failed to identify any benefit it conferred on the Defendants on which it could base a claim for unjust enrichment. Specifically, Bolton objects that: (1) the resources provided by St. John’s, i.e., Bolton’s salary, were provided to all faculty and staff of the university and are unrelated to discovery of the invention; and (2) that the research was performed off-campus at Ciba-Geigy, and hence St. John’s did not confer significant benefits on Defendants in relation to the inventions. (Bolton Mem. at 15; Spireas Mem. at 20; Bolton Reply at 9.)
St. John’s alleges that it provided Bolton and Spireas with the resources to conduct the research resulting in the inventions disclosed in the Liquisolid Patents. St. John’s has also alleged that while it provided these resources to Bolton and Spireas with the understanding that it would receive a share of any of the benefits of that research obtained by Bolton and Spireas, the two have failed to share those benefits with it and have retained the Liquisolid Patents and royalty payments for themselves. Furthermore, as discussed extensively in this Memorandum and Order, Plaintiffs allegations of Bolton’s and Spireas’s conduct with respect to the inventions “border[ ] on the larcenous and equity does not favor allowing [Bolton and Spireas] to escape restitution.”
Merrill Lynch,
Plaintiff has also stated a claim for unjust enrichment against Hygrosol. Plaintiff has alleged facts from which the court can infer that Hygrosol knew that St. John’s had a right to ownership of the Liquisolid Patents but entered into the assignment agreement with Bolton and Spireas and has retained them despite Plaintiffs rights to the Liquisolid Patents. Plaintiff has alleged a clear causal link between a wrongful act, (Bolton’s and Spireas’s breach of their contractual obligations), and Hygrosol’s enrichment, (the Liquisolid Patent assignments). This allegation is sufficient for the court to conclude that it would be unjust to allow Hygrosol to retain the Liquisolid Patents, and that Plaintiff has pleaded an equitable claim for unjust enrichment against Hygrosol.
2. Pleading Unjust Enrichment in the Alternative to Breach of Contract
Defendants argue that Plaintiff fails to state a cause of action for unjust enrichment, because the conduct alleged to form the basis of this claim is governed by the contracts alleged in the Complaint. (Bolton Mem. at 11, 13-15; Spireas Mem. at 15-16.) This argument is plainly premature.
Unjust enrichment is a quasi-contract claim viable only in the absence of an enforceable agreement between the parties governing the subject matter of the dispute.
Clark-Fitzpatrick,
At the pleading stage, Plaintiff is not required to guess whether it will be successful on its contract, tort, or quasi-contract claims. The Federal Rules of Civil Procedure explicitly permit Plaintiff to assert claims in the alternative. Under Rule 8(d)(2), “[a] party may set out 2 or more statements of a claim or defense alternatively or hypothetically, either in a single count or defense or in separate ones. If a party makes alternative statements, the pleading is sufficient if any one of them is sufficient.” Rule 8(d)(3) similarly provides that “[a] party may state as many separate claims or defenses as it has, regardless of consistency.” Rule 8(d), formerly Rule 8(e), embodies a liberal approach to pleading which favors the resolution of cases on the merits of the plaintiffs claims.
Henry v. Daytop Village,
The cases cited by Defendants are not to the contrary. Many courts dismissing tort and unjust enrichment claims as duplicative of contract claims have done so on a motion for summary judgment, with the benefit of a full factual record.
See, e.g., Beth Israel,
All of these cases make clear, however, that the threshold question is whether an enforceable contract exists that governs the subject matter underlying the unjust enrichment claim. Though Defendants may well establish that the conduct underlying these claims should be governed by the Agreements, Defendants may also establish that no valid contracts exist or that the breaches alleged by Plaintiff were not breaches of duties governed by the contracts. In fact, Bolton and Spireas dispute the scope and enforceability of the assignment and revenue-sharing terms in the Agreements as alleged.
(See
Opp. at 31-32 (citing Bolton Mem. at 4, 17-18; Spireas Mem. at 4-7).) Even if the Agreements are enforceable, the court must still interpret them to determine whether the unjust enrichment claims arise out of the same subject matter. On the present mo
3. Statute of Limitations
“ ‘Under New York law, an unjust enrichment claim accrues upon occurrence of the wrongful act giving rise to the duty of restitution.’ ”
Golden Pacific Bancorp,
The unjust enrichment claim against Hygrosol accrued when Hygrosol was unjustly enriched, i.e., the dates the Liquisolid Patents were assigned to Hygrosol. From the face of the Complaint the court cannot conclude that the assignments occurred more than six years before Plaintiff commenced this action, therefore the unjust enrichment claim against Hygrosol is timely. See supra Part II.C.4.a.
I. Plaintiffs Defenses to Application of the Statutes of Limitations
Though the statutes of limitations would ordinarily apply to bar some of Plaintiffs claims, two doctrines — the statutory discovery accrual rule for fraud claims and the doctrine of equitable tolling — if applicable, would render Plaintiffs claims timely. The applicability of these two doctrines depends in large part on the effect of the recordation and issuance of the Liquisolid Patents by the PTO.
“The New York statute of limitations for actual fraud is the longer of six years from the date on which the fraud occurred, or two years from the time when the plaintiff discovered or, with reasonable diligence, should have discovered the fraud.”
Serdarevic v. Advanced Medical Optics, Inc.,
merely incidental to the action.
See Kaufman,
As the court has already explained, Plaintiff has alleged that Defendants knowingly and deliberately breached their fiduciary duties of full disclosure to St. John’s and assigned the Liquisolid Patents to Hygrosol with the intent to deceive and defraud St. John’s. This fraud is not merely incidental but is essential to the action: Defendants’ breaches of their agreements with Plaintiff and their fraudulent concealment of those breaches are the two principal grievances expressed in the Complaint. Plaintiffs claims for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, fraud, and fraudulent conveyance are all predicated on an allegation of actual fraud and are therefore subject to the fraud discovery accrual rule.
2. Equitable Tolling 24
“A defendant may be estopped from pleading the Statute of Limitations where a plaintiff was induced by fraud, misrepresentation, or deception to refrain from timely commencing an action.”
Gleason v. Spota,
Plaintiff has alleged that a special relationship of trust and confidence existed between it and Bolton and Spireas, such that Bolton and Spireas owed St. John’s a fiduciary duty to disclose to St. John’s material facts relating to their research. By failing to disclose their assessment of the value of their research at St. John’s or the Liquisolid Patents that resulted from that research, Plaintiff alleges that Bolton and Spireas prevented St. John’s from learning of and asserting its contractual rights to the Liquisolid Patents and licensing revenues, and that they have been harmed because they have not received the benefit of their contractual rights. Moreover, Plaintiff alleges Bolton’s and Spireas’s failure to disclose was fraudulent because they intentionally remained silent, in spite of their duty to disclose, to prevent Plaintiff from learning of its rights to the Liquisolid Patents and royalties. Plaintiffs allegations are sufficient to invoke the court’s power to toll the statutes of limitations applicable to Plaintiffs claims.
However, “equitable estoppel does not apply where the misrepresentation or act of concealment underlying the estoppel claim is the same act which forms the basis of plaintiffs underlying cause of action.”
Kaufman,
“Equitable estoppel will not toll a limitations statute ... where a plaintiff possesses timely knowledge sufficient to place him or her under a duty to make inquiry and ascertain all the relevant facts prior to the expiration of the applicable Statute of Limitations.”
Gleason v. Spota,
Bolton and Spireas contend that issuance of the Liquisolid Patents by the PTO gave St. John’s constructive notice that their research at St. John’s had produced patentable discoveries, and that in the exercise of reasonable diligence Plaintiff should have learned of both the fraud and the facts underlying its claims on the dates the Liquisolid Patents issued. (Bolton Mem. at 6-10; Spireas Mem. at 10-11.)
Bolton’s and Spireas’s arguments raise three questions: (1) Whether a rule of federal law requires the court to impute knowledge of the Liquisolid Patents’ existence and contents to Plaintiff on their dates of issuance in this case; (2) If not, whether New York law requires the court to impute knowledge of the Liquisolid Patents to Plaintiff on their dates of issuance; and (3) Whether Spireas’s disclosure of his dissertation was sufficient to put St. John’s on inquiry notice.
a. Constructive Notice of Patent Issuance under Federal Law
In some of its older patent law jurisprudence, the Supreme Court has, on occasion, stated the principle that “issuance of a patent and recordation in the Patent Office constitutes notice to the world of its existence.”
Wine Ry. Appliance Co. v. Enterprise Ry. Equipment Co.,
The cases relating to the constructive notice of a patent’s existence do not bear the weight Defendants place on them. The Federal Circuit has confronted what significance, if any, to accord this language in the context of suits brought by purported co-inventors to correct the inventorship of a patent under 35 U.S.C. § 256. The questions presented in inventorship cases are analogous to those presented here. An inventorship action may be brought at any time during the life of the patent, but a purported inventor may be estopped under the doctrine of laches from contesting
In
Advanced Cardiovascular
the lower court granted a motion to dismiss on the basis of laches after calculating the period of delay running from the date the patent issued.
Id.
The district court explicitly relied on
Sontag Chain Stores,
On appeal, the Federal Circuit explicitly repudiated this argument, holding that “Sontag Chain Stores harbors no principles applicable to laches. Constructive notice is not an appropriate substitute for the determination of reasonableness or excuse for delay.” Id. at 1162 (emphasis added). Analogizing the application of laches in an inventorship suit to the application of laches to a patentee’s suit for infringement, the court explained that while certain provisions of patent law involve constructive notice, where equitable considerations come into play, actual knowledge of the existence of a plaintiffs claim, or of facts supporting a duty of inquiry, is required. Id. In stating that the period of delay cannot “start while the potential claimant remains ignorant that a cause of action has arisen,” the court rejected the argument advanced by Defendants here, and held that mere issuance of a patent does not give a potential claimant notice of the patent’s existence for purposes of determining whether the potential claimant exercised diligence in protecting his rights. Id.
Though Defendants cite cases in which federal district courts have read
Wine Railway
and
Sontag Chain Stores
in the literal manner they suggest, the court is unpersuaded by their reasoning and declines to adopt it.
25
In
M & T Chemicals, Inc. v. International Business Machines Corp.,
In
M & T
and
Rodgard,
the courts reflexively accepted the
Sontag Chain Stores
language as a literally correct statement of the law, without considering whether doing so was an appropriate extension of the language from the substantive context in which it appears in
Sontag Chain Stores
and
Wine Railway.
In
Advanced Cardiovascular,
the court carefully considered whether the underlying substantive law to which laches would apply in that case, 35 U.S.C. § 256, would be advanced by imputing knowledge of the patents to the plaintiff, or whether a different standard was more appropriate.
See, e.g.,
As
Wine Railway, Sontag Chain Stores,
and
Advanced Cardiovascular
demonstrate, the applicability of the principle of constructive notice of a patent, if it exists at all, is inextricably intertwined with the specific policy objectives fundamental to the underlying substantive federal patent law. The federal policy concerns implicit in the Supreme Court’s application of constructive notice to the underlying substantive federal law at issue in the cases cited by
Defendants
— ie., the defense of intervening rights to patent infringement
(Sontag Chain Stores,
b. Constructive Notice of Patent Issuance under New York State Law
Because patents have the attributes of personal property,
see
35 U.S.C. § 261, the transfer of patents and property rights of individuals in patents are governed by state law.
Stanford,
The standard adopted in Advanced Cardiovascular for determining whether a potential claimant knew or should have known of his cause of action or that he has been defrauded is, for all intents, identical to that employed by New York courts in determining whether a plaintiff had notice of his claim sufficient to defeat equitable tolling or would, through reasonable diligence, have discovered that he was being defrauded. For much the same reasons Advanced Cardiovascular rejected the Sontag Chain Stores dictum’s applicability to the equitable doctrine of laches in an inventorship suit, the court finds that a doctrine imputing notice of the Liquisolid Patents on the date of issuance would be similarly inconsistent with the doctrine of equitable tolling or the application of the fraud discovery accrual rule under New York law.
In articulating the principle underlying the doctrine of equitable tolling, the New York Court of Appeals has looked to Supreme Court precedent and the “ ‘the maxim that no man may take advantage of his own wrong.’ ”
General Stencils, Inc. v. Chiappa,
The Supreme Court has stated that “the law imputes knowledge when opportunity and interest, combined with reasonable care, would necessarily impart it. Not to
Plaintiff has repeatedly alleged that it had no knowledge of the Liquisolid Patents or their relationship to the Defendants’ research at St. John’s until November 2008, at which time it promptly demanded performance of Defendants’ obligations under the Agreements. For the most part, Defendants do not argue that Plaintiff was aware of circumstances that should have caused it to investigate the public records of the PTO to determine whether Defendants had obtained patents related to research performed at St. John’s. Defendants argue instead, that Plaintiff should be charged with knowledge of the Liquisolid Patents simply by virtue of their existence. New York courts impute knowledge of the contents of a public record only where a reasonable person would have investigated it. Therefore, it is appropriate to frame Defendants’ argument in terms of the duty they assert a reasonable person in Plaintiffs position would be under if this court were to accept their argument. Defendants would have this court hold that a “reasonably diligent” or “ordinarily suspicious” university has a duty to review all patents issued by the PTO to all former students, faculty, and staff, in the absence of any information suggesting it has an interest in the contents of the patents issued, or that such patents will reveal evidence it is being defrauded.
This degree of watchfulness is not required by New York law. Defendants have not directed the court to a reasoned opinion in which a court has found that a “reasonable person” or a “person of ordinary suspicion” has a continuing duty to monitor a public record in the absence of any information which should trigger the person’s interest in the record, on the off-chance that it might reveal evidence that he has been defrauded. Therefore, the court finds that New York law does not
c. Inquiry Notice
In the alternative, Defendants, point to one fact that might have put St. John’s on inquiry notice of its claims to the inventions or of Bolton’s and Spireas’s intended fraud. Defendants argue that Spireas’s submission of his dissertation and oral defense put St. John’s on inquiry notice of its rights to the research disclosed in the dissertation. (Bolton Mem. at 7 n. 5; Spireas Mem. at 8 n. 4, n. 5; Spireas Reply at 8 n. 20.)
The determination whether a plaintiff was “possessed of knowledge of facts from which it could [] reasonably have inferred ... the alleged fraud” is “[o]rdinarily ... a mixed question of law and fact.”
Erbe v. Lincoln Rochester Trust Co.,
Even if the court accepts as true the proposition that Spireas’s dissertation fully disclosed to St. John’s
26
the nature and findings of the research he conducted, it is not necessarily clear that this alone was sufficient to satisfy Bolton’s and Spireas’s fiduciary duties to disclose material facts relating to the inventions. Not all research disclosed in dissertations is valuable or patentable, and the court cannot conclude from the mere fact of the submission of the dissertation to the St. John’s faculty review panel that a reasonable person on the faculty panel reviewing it would have known that the research was valuable and should have acted accordingly. It is even more difficult for Defendants to argue that the dissertation and oral defense put St. John’s on notice of Bolton’s and Spieras’s fraud. There is nothing inherently fraudulent about submitting and defending a dissertation, and in the absence of evidence that the dissertation demonstrated Defendants’ wrongful intent to appropriate the research for their own ends, the court cannot conclude that an ordinarily suspicious person on the faculty review panel would have been placed on notice of Defendants’ fraud. But the import of Spireas’s purported disclosure is a question of fact the court cannot resolve on a motion to dismiss. Because the parties contest the nature and significance of the facts disclosed in the dissertation and oral defense, the court cannot conclude on a motion to dismiss that the dissertation and oral defense should have placed St. John’s on
Taking Plaintiffs factual allegations as true, the court finds that the first day on which Plaintiff could with reasonable diligence have discovered it was being defrauded and the facts forming the basis of its claims, was the day on which it was alerted of the similarities between Spireas’s doctoral dissertation and the Liquisolid Patents. That date was in or around November 2008. For those claims that do not sound in fraud, including the contract, tortious interference with contract, conversion, and unjust enrichment claims, Plaintiff has alleged facts sufficient to invoke equitable tolling of the applicable statutes of limitations until November 2008, and Defendant’s motions to dismiss these claims as untimely must be denied. Plaintiffs claims subject to the fraud discovery accrual rule, including Plaintiffs fraudulent concealment, fraudulent conveyance, breach of fiduciary duty, and aiding and abetting breach of fiduciary duty claims, are also timely because Plaintiff originally filed this action within two years of November 2008.
II. CONCLUSION
Nearly every defense raised by Defendants implicates a question of fact that cannot be resolved by the court on a motion to dismiss. While it is entirely possible that Defendants will be able to establish their entitlement to summary judgment on some or all of these defenses following discovery, the court cannot say that Plaintiffs sixty-one page Complaint is legally insufficient. The court advises the parties that it will permit each only one motion for summary judgment at the close of discovery. If upon reviewing the motions for summary judgment the court concludes that there are genuine issues of material fact in dispute, the court will move expeditiously to trial and will expect the parties to be prepared accordingly.
For the foregoing reasons, Defendants’ motions to dismiss are DENIED. Defendants shall answer the Complaint by January 10, 2011, and the parties shall proceed with discovery forthwith.
SO ORDERED.
Notes
. Except where indicated below, the following allegations of fact are drawn from Plaintiff's Complaint and are accepted as true for purposes of deciding the motions to dismiss under Fed.R.Civ.P. 12(b)(6). All other facts are drawn from documents integral to the Complaint or of which judicial notice may be taken.
See Chambers v. Time Warner, Inc.,
. The dissertation and the research it describes are integral to the Complaint because Plaintiff relied on the dissertation and its description of the research in drafting the Complaint.
(See
Compl. ¶¶ 22-25; Pl.'s Opp'n ("Opp.”) (Docket Entry #37) at 3 n. 1.)
See Chambers,
. "Inventor” is a term of art under patent law, see, e.g., 35 U.S.C. § 111 (patent application to be filed by the inventor), and it is used as such in this Memorandum and Order.
. Bolton and Spireas filed the first patent application, United States Patent Application No. 08/658,514 (the " '514 Application”) in June 1996. (McElroy Decl. Ex. A.) In September 1998, the U.S. Patent and Trademark Office ("PTO”) issued Patent No. 5,800,834 on the '514 Application (the " '834 Patent”). (Id.) Bolton and Spireas filed an application for a second patent in October 1997 and the PTO issued Patent No. 5,968,550 on the application in October 1999 (the " '550 Patent”). (McElroy Decl. Ex. B.) Bolton and Spireas filed an application for a third patent in August 1998 and the PTO issued Patent No. 6,096,337 on the application in August 2000 (the " '337 Patent”). (McElroy Decl. Ex. C.) Spireas filed an application for a fourth patent in May 2000 and the PTO issued Patent No. 6,423,339 on the application in July 2002 (the " '339 Patent”). (McElroy Decl. Ex. D.)
The court takes judicial notice of the patents’ issuance and contents under Federal Rule of Evidence 201 because the patents are documents issued by the PTO, and are "capable of accurate and ready determination by resort to sources whose accuracy cannot reasonably be questioned.”
See In re Chippendales USA, Inc.,
. Spireas was employed by St. John’s as a paid research/teaching fellow from September 1988 to May 1990. (Id. 11 21.)
. The Bolton Research Agreement is integral to the Complaint because Plaintiff relied on it in drafting the Complaint. (See Compl. ¶¶ 47-50.)
. The court declines Spireas’s and Hygrosol’s invitation to order Plaintiff to amend its Complaint and attach copies of the Agreements. (Spireas’s and Hygrosol’s Reply Mem. ("Spireas Reply”) (Docket Entry # 42) at In. 1.) As explained in this Memorandum and Order, Plaintiff s allegations of fact are sufficient for the purposes of the present motions to dismiss, and Plaintiff is not required to submit the Agreements to the court at this early stage of the litigation.
. Bolton further argues, however, that the '339 Patent is not substantially related to the others because only the specifications section of the patent is similar to the other Liquisolid Patents, while the claims section “is completely different from the research and conclusions contained in Spireas’ dissertation.’’ (Bolton Reply at 6 n. 4.) Whether the '339 Patent is sufficiently dissimilar from the research disclosed in Spireas's dissertation to warrant a determination that it does not derive “in whole or in part” from research conducted at St. John’s is a mixed question of law and fact the court cannot resolve on a motion to dismiss. See infra Part II.C.3.
. Plaintiff alleges that Bolton was listed as an inventor on the patent application that resulted in the '339 Patent (Compl. ¶ 32), but Bolton was not listed as an inventor of the resulting '339 Patent (McEIroy Decl. Ex. D).
. The court takes judicial notice of the fact that the Liquisolid Patents were assigned to Hygrosol no later than October 12, 2006, the date on which Hygrosol recorded the assignments with the PTO under 35 U.S.C. § 261. See US PTO Assignments on the Web, Patent Assignee Summary, http://assignments.uspto. gov/assignments/?db=pat (insert "Hygrosol” into search field "Assignee name” and click "Search” button).
When Hygrosol recorded the assignments, Hygrosol represented to the PTO that Bolton and Spireas executed all four assignments on June 1, 1998, before Bolton and Spireas had even filed some of the patent applications that resulted in the Liquisolid Patents. See USP-TO Assignments on the Web, Patent Assignee Summary, http://assignments.uspto.gov/ assignments/?db=pat (insert "Hygrosol” into search field "Assignee name” and click "Search” button; click hyperlink of patent number under "PAT# "; find the patent assignment execution date under "Exec Dt”). Whether the assignments actually occurred on that date or at some other time is a mixed question of law and fact the court cannot resolve on a motion to dismiss, and without any of the relevant facts.
. St. John’s sued the Defendants on November 18, 2008, by filing a Notice and Summons in New York Supreme Court, Queens County. Spireas rerftoved the action to this court on December 15, 2008. (Notice of Removal (Docket Entry # 1).) Plaintiff subsequently filed this Complaint on March 4, 2009. (See Compl.) For purposes of the statutes of limitations, the action was commenced and the statutes of limitations ceased to run on November 18, 2008.
. Bolton and Spireas also argue that they openly repudiated any fiduciary obligation they may have had when they filed applications for the Liquisolid Patents. This argument merely restates the argument advanced by Defendants that issuance of the Liquisolid Patents gave constructive notice of Bolton’s and Spireas’s breach to Plaintiff, and the court rejects this argument for the same reasons. See infra Part II.1.3.
. Even if the fiduciary relationship terminated more than six years before the commencement of this action, the breach of fiduciary duty claims sound in fraud and may claim the benefit of the two-year discovery accrual rule applicable to fraud claims. See infra Part II.I.l.
. It is unclear whether Plaintiff’s allegations of fact satisfy all elements of a claim for an accounting, but because Defendants' challenge to the accounting claim addressed only whether there was an underlying fiduciary relationship, the court does not reach other possible challenges.
See Pressman v. Estate of Steinvorth,
.
Compare Kronish Lieb Weiner & Heilman LLP v. Tahari, Ltd.,
. Plaintiff has also alleged that Hygrosol is the alter ego of Bolton and Spireas. (Compl. ¶ 162.) While this allegation is a conclusion of law the court gives no weight in deciding this motion, it is notable in that it is one of the few claims Defendants have not attacked in their briefs.
. See supra Part II.C.4.a n. 10.
. See 35 U.S.C. §§111 (patent application to be made by inventor), 116 (joint inventors to file jointly), 118 (application by others only as agent for inventor), 152 (patent issued to assignee if designated on application), 261 (applicant or his assigns owns patent; patent to be treated as personal property and subject to assignment).
. See supra Part II.C.4.a n. 10.
. See supra Part II.C.4.a n. 10.
. See supra Part II.C.4.a n. 10.
. While Plaintiff's separate allegations that the assignments to Hygrosol were fraudulent conveyances and that Hygrosol is the alter ego of Bolton and Spireas are arguably inconsistent with the theory that Hygrosol was a bona fide purchaser for value and without notice, Plaintiff is permitted to plead causes of action in the alternative, and on a motion to dismiss the court may not dismiss an alternative claim if there are allegations of fact in the Complaint sufficient to state a claim for relief.
See infra
Part II.H.2. Because there is at least one plausible theory of conversion
.
See, e.g., King's Choice Neckwear,
. Some federal courts in this Circuit, and New York state courts, have attempted to draw a distinction between the doctrines of equitable estoppel and equitable tolling. But generally, "New York courts use the terms interchangeably 'to cover both the circumstances where the defendant conceals from the plaintiff the fact that he has a cause of action and where the plaintiff is aware of his cause of action, but the defendant induces him to forego suit until after the period of limitations has expired. ”
Coleman & Co. Securities, Inc. v. Giaquinto Family Trust,
.
This court is not the first to react with skepticism to the argument that the
Sontag Chain StoresfWine Railway
dicta should be applied literally in the statute of limitations context.
See Applera Corporation-Applied Biosystems Group
v.
Illumina, Inc.,
No. C 07-02845 WHA,
. The parties have not briefed the question whether disclosure to the members of the faculty panel reviewing the dissertation and hearing the oral defense would be sufficient to constitute notice to St. John’s, and the court does not reach this issue.
